|
SUPT4H1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.06710000023081E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.88750000005034E-06 |
| Normal-vs-Stage2 |
3.380000E-01 |
| Normal-vs-Stage3 |
5.53970000000126E-05 |
| Normal-vs-Stage4 |
7.9577999967384E-08 |
| Stage1-vs-Stage2 |
7.862300E-02 |
| Stage1-vs-Stage3 |
6.228000E-01 |
| Stage1-vs-Stage4 |
3.039500E-02 |
| Stage2-vs-Stage3 |
6.622100E-02 |
| Stage2-vs-Stage4 |
8.019300E-03 |
| Stage3-vs-Stage4 |
1.441200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.63719999954648E-07 |
| Normal-vs-AfricanAmerican |
1.144150E-02 |
| Normal-vs-Asian |
3.866100E-02 |
| Caucasian-vs-AfricanAmerican |
9.752600E-01 |
| Caucasian-vs-Asian |
2.955200E-01 |
| AfricanAmerican-vs-Asian |
4.734400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.3182000000197E-06 |
| Normal-vs-Female |
4.62919999999478E-06 |
| Male-vs-Female |
4.094400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.87659999999879E-05 |
| Normal-vs-Age(41-60Yrs) |
7.85819999999937E-05 |
| Normal-vs-Age(61-80Yrs) |
2.00849999999475E-05 |
| Normal-vs-Age(81-100Yrs) |
7.614000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.437400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.459200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.309700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.223200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.083750E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.420300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.065600E-01 |
| Classical-VS-Follicular |
7.123400E-01 |
| Classical-VS-Other |
3.331200E-01 |
| Classical-VS-Normal |
4.36970000000647E-05 |
| Tall-VS-Follicular |
5.117400E-01 |
| Tall-VS-Other |
6.702600E-01 |
| Tall-VS-Normal |
8.172100E-04 |
| Follicular-VS-Other |
5.221600E-01 |
| Follicular-VS-Normal |
1.844770E-03 |
| Other-VS-Normal |
9.057700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.612800E-04 |
| Normal-vs-N1 |
7.33240000050372E-07 |
| N0-vs-N1 |
2.109800E-02 |
|
|
